| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa10 |
| Uniprot No | Q9GZZ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-240aa |
| 氨基酸序列 | AEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLEVTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYNKADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGHQLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYV |
| 预测分子量 | 51.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNa10(胆碱能受体尼古丁α10亚基)重组蛋白的3篇代表性文献示例，基于领域内相关研究方向的概括整理：
1. **文献名称**：*"Recombinant expression and functional characterization of the α10 nicotinic acetylcholine receptor subunit in mammalian cells"*
**作者**：Smith J, et al.
**摘要**：本研究成功在HEK293细胞中重组表达了CHRNa10蛋白，并验证了其与α9亚基形成功能性离子通道的能力。通过电生理学实验，证实重组α9α10受体对乙酰胆碱及尼古丁的响应特性，揭示了其在听觉信号传导中的潜在作用。
2. **文献名称**：*"Purification and structural analysis of the human α10 nicotinic receptor subunit using a baculovirus-insect cell system"*
**作者**：Zhang L, et al.
**摘要**：作者利用杆状病毒-昆虫细胞系统高效表达并纯化人源CHRNa10重组蛋白，通过冷冻电镜技术解析了其胞外域结构，阐明了该亚基与配体结合的分子机制，为靶向药物设计提供了结构基础。
3. **文献名称**：*"Role of recombinant α10 nAChR in breast cancer cell proliferation and migration"*
**作者**：Wang Y, et al.
**摘要**：该研究通过体外重组CHRNa10蛋白，发现其在乳腺癌细胞中异常激活可促进细胞迁移和侵袭，提示α10可能作为癌症治疗的潜在靶点。实验采用siRNA敲低和重组蛋白回补策略验证其功能。
---
**注**：以上文献信息为示例性概括，实际文献可能需要通过PubMed或Google Scholar检索关键词如“CHRNA10 recombinant”“alpha10 nicotinic receptor expression”获取。如需具体文章，可进一步提供研究方向(如结构、疾病关联等)以便精准推荐。
**Background of CHRNa10 Recombinant Protein**
The CHRNA10 (cholinergic receptor nicotinic alpha 10 subunit) recombinant protein is a biologically engineered form of the α10 subunit of the nicotinic acetylcholine receptor (nAChR) family. nAChRs are ligand-gated ion channels that mediate synaptic signaling in response to acetylcholine and other agonists, playing critical roles in neuromuscular and central nervous system functions. The α10 subunit, often co-expressed with α9 in heteromeric receptors, is predominantly found in non-neuronal tissues and specialized sensory cells, such as cochlear hair cells in the inner ear, where it contributes to auditory processing and neurotransmitter release.
Recombinant CHRNA10 is produced using in vitro expression systems (e.g., bacterial, yeast, or mammalian cell lines) to ensure high purity and functionality. Its production enables detailed studies of receptor assembly, ligand binding, and ion channel gating mechanisms. Structurally, the α10 subunit contains an extracellular ligand-binding domain, a transmembrane region forming the ion pore, and intracellular regulatory sites. Unlike other nAChR subunits, α9 and α10 form receptors with unique calcium permeability, linking them to intracellular signaling pathways and cochlear amplification.
Research on CHRNA10 has implications for understanding hearing loss, tinnitus, and neuropathic pain, as α9α10 receptors modulate auditory neurotransmission and inflammatory responses. Dysregulation of these receptors is also associated with certain cancers, suggesting potential roles in tumorigenesis. Recombinant CHRNA10 serves as a tool for drug discovery, enabling screening of therapeutics targeting hearing disorders or chronic pain. Additionally, its study aids in elucidating the evolutionary divergence of nAChRs and their tissue-specific functions, bridging gaps between molecular biology and sensory physiology.
×
